Compare · BGLC vs ELV
BGLC vs ELV
Side-by-side comparison of BioNexus Gene Lab Corp (BGLC) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BGLC and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $96.42B, about 40036.2x BGLC ($2.4M).
- ELV has been more active in the news (5 items in the past 4 weeks vs 1 for BGLC).
- ELV has more recent analyst coverage (23 ratings vs 0 for BGLC).
- Company
- BioNexus Gene Lab Corp
- Elevance Health Inc.
- Price
- -
- -
- Market cap
- $2.4M
- $96.42B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 5
- Recent ratings
- 0
- 23
ELV
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest BGLC
- BioNexus Launches New Corporate Website with Expanded Business and Investor Resources
- SEC Form 8-K filed by BioNexus Gene Lab Corp
- RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
- Chief Executive Officer Tan Lee Su-Leng was granted 338,709 shares (SEC Form 4)
- Director Yap Chee Keong was granted 32,258 shares (SEC Form 4)
- Director Bin Abdul Hamid Muhammad Azrul was granted 32,258 shares (SEC Form 4)
- Chief Financial Officer Chong Set Fui was granted 96,774 shares (SEC Form 4)
- Director Low Jook Yuen was granted 16,129 shares, increasing direct ownership by 1,279% to 17,390 units (SEC Form 4)
- SEC Form 10-Q filed by BioNexus Gene Lab Corp
- New insider Fidelion Diagnostics Pte. Ltd. claimed ownership of 392,329 shares (SEC Form 3)
Latest ELV
- From Confusion to Clarity: Consumers See a Role for AI in Simplifying Healthcare, Elevance Health/Harris Poll Survey Finds
- AM Best Assigns Indicative Issue Credit Ratings to Elevance Health, Inc.’s New Shelf Registration
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- EVP & Chief Digital Info Ofr Lavu Ratnakar sold $572,000 worth of shares (1,300 units at $440.00), decreasing direct ownership by 8% to 14,849 units (SEC Form 4)
- SEC Form S-3ASR filed by Elevance Health Inc.
- EVP & CFO Kaye Mark sold $4,658,357 worth of shares (10,584 units at $440.13) (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Names Jeff Park President of Carelon
- SEC Form 8-K filed by Elevance Health Inc.
- Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance